RemeGen Co., Ltd. (OTCMKTS:REGMF) Sees Large Decline in Short Interest

RemeGen Co., Ltd. (OTCMKTS:REGMF) saw a significant decline in short interest in February. As of February 28th, there was short interest totalling 340,500 shares, a decline of 70.6% from the February 13th total of 1,157,500 shares. Based on an average daily volume of 1,100 shares, the short-interest ratio is presently 309.5 days.

RemeGen Price Performance

Shares of REGMF stock remained flat at $1.50 during trading hours on Thursday. The firm has a 50-day moving average price of $1.50 and a 200 day moving average price of $1.56. RemeGen has a 1 year low of $1.50 and a 1 year high of $4.00.

RemeGen Company Profile

RemeGen Co, Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers.